Cardio Care Live

Online Events

Heart Failure

  • CME
    0.5

    Heart Failure Snapshot

    Speakers:Akshay Suvas Desai, MD, MPH, Associate Professor of Medicine
    James L. Januzzi, Jr., MD, FACC, FESC, Professor of Medicine

    Duration: 30 minutes

    Presented on: September 27, 2016

  • CME
    1.0

    State of the Art Pharmacotherapy for Heart Failure with Reduced Ejection Fraction

    Speakers:Akshay Suvas Desai, MD, MPH, Associate Professor of Medicine
    James L. Januzzi, Jr., MD, FACC, FESC, Professor of Medicine

    Duration: 60 minutes

    Presented on: September 27, 2016

  • CME
    0.5

    Game Changing Devices for Heart Failure: Electricity & Catheter-based Therapies

    Speakers:Jagmeet Singh, MD, DPhil, FHRS, Professor of Medicine

    Duration: 30 minutes

    Presented on: September 27, 2016

  • CME
    1.0

    Heart Failure Management Today and Tomorrow: A Roundtable Discussion

    Speakers:Akshay Suvas Desai, MD, MPH, Associate Professor of Medicine
    Jagmeet Singh, MD, DPhil, FHRS, Professor of Medicine
    James L. Januzzi, Jr., MD, FACC, FESC, Professor of Medicine

    Duration: 60 minutes

    Presented on: November 1, 2016

Anticoagulation

  • CME
    1.0

    Anticoagulation in the Era of Newer Target-Specific Oral Agents

    Speakers:Christian T. Ruff, MD, MPH, TIMI Study Group
    Elaine Hylek, MD, MPH, Professor of Medicine

    Duration: 60 minutes

    Presented on: October 7, 2016

Pulmonary Arterial Hypertension

  • CME
    1.0

    Evolutionary Approaches to the Patient with Pulmonary Arterial Hypertension

    Speakers:Harrison W. Farber, MD, FAHA, FCCP, Professor of Medicine, Pulmonary Hypertension Center

    Duration: 60 minutes

    Presented on: June 28, 2016

Speakers

Heart Failure

  • Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Associate Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.
  • James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    Professor of Medicine

    James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School and a faculty member at the Harvard Clinical Research Institute. His research has contributed to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. Dr Januzzi has published numerous manuscripts, book chapters and review articles, and has edited two text books on cardiac biomarker testing. He serves on the editorial board of numerous scientific journals, and is currently the chair of the ACC Task Force on Consensus Statements. He earned his MD from New York Medical College.
  • Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.

Anticoagulation

  • Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    TIMI Study Group

    Christian T. Ruff, MD, MPH, is an associate physician in the Cardiovascular Division at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts. His expertise lies in atrial fibrillation, both risk stratification and implementation of antithrombotic therapy for stroke prevention, as well as the treatment and prevention of venous thromboembolism. Dr Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, is director of the Genetics Core Laboratory, and co-chairman of the Clinical Events Committee. He earned his medical degree at the Johns Hopkins University School of Medicine and his master of public health degree at the Harvard School of Public Health.
  • Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Professor of Medicine

    Elaine M. Hylek, MD, MPH, is a professor of medicine and Associate Director of the Education and Training Division of the Boston University’s Cardiovascular Institute’s Training Program. She received her MD from the University of Pittsburgh School of Medicine and her MPH from Harvard University School of Public Health. Dr Hylek’s research areas include arterial (stroke) and venous thrombosis, anticoagulant therapies, and atrial fibrillation. Recent investigations have included the role of biomarkers in atrial fibrillation related stroke, factors associated with major hemorrhage and antithrombotic therapy, and the efficacy and safety of novel oral anticoagulant drugs. She is a section editor for Thrombosis and Haemostasis, and serves on various committees and data safety monitoring boards.

Pulmonary Arterial Hypertension

  • Harrison W. Farber, MD, FAHA, FCCP

    Harrison W. Farber, MD, FAHA, FCCP

    Harrison W. Farber, MD, FAHA, FCCP

    Professor of Medicine, Pulmonary Hypertension Center

    Harrison W. Farber, MD, is Professor of Medicine and Director of the Pulmonary Hypertension Center at Boston University/Boston Medical Center. With a research focus on endothelial cell biology, his laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, scleroderma, and left ventricular diastolic dysfunction. Dr Farber is an NIH-funded principle investigator on numerous grants, and is a member of several research groups both within the Pulmonary Hypertension Center and other divisions within the Department of Medicine.

All Speakers

  • Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Akshay Suvas Desai, MD, MPH

    Associate Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.
  • James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    James L. Januzzi, Jr., MD, FACC, FESC

    Professor of Medicine

    James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School and a faculty member at the Harvard Clinical Research Institute. His research has contributed to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. Dr Januzzi has published numerous manuscripts, book chapters and review articles, and has edited two text books on cardiac biomarker testing. He serves on the editorial board of numerous scientific journals, and is currently the chair of the ACC Task Force on Consensus Statements. He earned his MD from New York Medical College.
  • Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Jagmeet Singh, MD, DPhil, FHRS

    Professor of Medicine

    Jagmeet P. Singh, MD, PhD, is a professor of medicine at Harvard Medical School and the associate chief of the Cardiology Division at Massachusetts General Hospital, both located in Boston. He is also the founder and the director of the Resynchronization and Advanced Cardiac Therapeutics Program. His research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. He is the principal investigator and a member of steering committees for over 20 active single- and multi-center research studies. Dr Singh earned his MD from BJ Medical College, Pune University, India, and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Massachusetts General Hospital.
  • Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    TIMI Study Group

    Christian T. Ruff, MD, MPH, is an associate physician in the Cardiovascular Division at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts. His expertise lies in atrial fibrillation, both risk stratification and implementation of antithrombotic therapy for stroke prevention, as well as the treatment and prevention of venous thromboembolism. Dr Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, is director of the Genetics Core Laboratory, and co-chairman of the Clinical Events Committee. He earned his medical degree at the Johns Hopkins University School of Medicine and his master of public health degree at the Harvard School of Public Health.
  • Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Professor of Medicine

    Elaine M. Hylek, MD, MPH, is a professor of medicine and Associate Director of the Education and Training Division of the Boston University’s Cardiovascular Institute’s Training Program. She received her MD from the University of Pittsburgh School of Medicine and her MPH from Harvard University School of Public Health. Dr Hylek’s research areas include arterial (stroke) and venous thrombosis, anticoagulant therapies, and atrial fibrillation. Recent investigations have included the role of biomarkers in atrial fibrillation related stroke, factors associated with major hemorrhage and antithrombotic therapy, and the efficacy and safety of novel oral anticoagulant drugs. She is a section editor for Thrombosis and Haemostasis, and serves on various committees and data safety monitoring boards.
  • Harrison W. Farber, MD, FAHA, FCCP

    Harrison W. Farber, MD, FAHA, FCCP

    Harrison W. Farber, MD, FAHA, FCCP

    Professor of Medicine, Pulmonary Hypertension Center

    Harrison W. Farber, MD, is Professor of Medicine and Director of the Pulmonary Hypertension Center at Boston University/Boston Medical Center. With a research focus on endothelial cell biology, his laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, scleroderma, and left ventricular diastolic dysfunction. Dr Farber is an NIH-funded principle investigator on numerous grants, and is a member of several research groups both within the Pulmonary Hypertension Center and other divisions within the Department of Medicine.
 

Partners

Academic

  • logo-einstein

Associations